Who is Claritas pharmaceuticals?

About Claritas PharmaceuticalsClaritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.

Can Claritas update or revise any forward-looking information?

Claritas disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Contact InformationRobert FarrellPresident, CEO (888) [email protected]

Does Claritas have a nitric oxide releasing compound?

Claritas is currently developing R-107, its proprietary nitric oxide-releasing compound, for the treatment of viral infections, including COVID-related ARDS, and COVID-related sepsis. Under the License Amendment, Claritas will now have world-wide rights to develop R-107 for the treatment of pulmonary diseases, including PAH and PPHN.

Does Claritas pay a royalty?

During the applicable term of any patent covering R-107 in the treatment of PAH, Claritas will pay to Salzman Group, Inc. a royalty of eight percent (8%) of the net sales for all R-107 products for the treatment of PAH